Global  

Celebrating 10 Years of Trusted News Discovery
One News Page
> >

Avalon GloboCare launches first-in-human study of AVA-001 for leukemia, non-Hodgkin lymphoma

Proactive Investors Monday, 15 July 2019
Avalon GloboCare Corp (NASDAQ:AVCO) on Monday provided an update of four clinical programs in cellular therapy, noting that AVA-001 entered into this month the first-in-human clinical study for relapsed/refractory B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma. The study of AVA-001, which is a leverage individualized CAR (Chimeric Antigen Receptor) T-cell therapy candidate for immuno-oncology, is being conducted at the Hebei Yanda Lu Daopei Hospital and Beijing Lu Daopei Hospital in China, the world’s single largest CAR-T treatment network with over 600 patients. The significance of CAR-T cells is that they have been engineered to express a receptor (CAR) that recognizes a specific cancer surface target to attack. Unlike traditional small molecule or biologic treatments, the CAR-T therapies are specifically manufactured for each individual patient. READ:Avalon GloboCare adds Cornell cellular therapy director to its advisory board Avalon said the clinical trial of AVA-001 could result in a more powerful delivery mechanism designed to treat the individual patient. The company expects to recruit 20 patients for safety and efficacy studies of AVA-001. The company also said its proprietary, transposon-based, multi-targeted CAR-T candidate, AVA-101, will enter the pre-clinical process development and validation phase during the third quarter of 2019 as scheduled. Avalon, based in Freehold, New Jersey, said it could launch the first-in-human clinical trial of this next-generation of safer and more efficacious CAR-T candidate during first quarter of 2020. The company has further developed a novel therapeutic candidate, AVA-201, for oral cancer. The company plans to launch the first-in-human clinical trial for AVA-201 during the fourth quarter of 2019 with the expectation to move toward a regulatory filing in the fourth quarter of 2020. Treating diabetic foot ulcer Lastly, Avalon said it is developing a clinical-grade, exosome-based therapeutic candidate, AVA-202, and plans to initiate international multi-centered clinical studies of vascular diseases and wound healing, including treatment of diabetic foot ulcer, during the fourth quarter of 2019. “We are pleased to provide updates on our progress in advancing clinical studies using our cellular therapeutic platforms in CAR-T and stem cell derived exosomes,” said CEO Dr David Jin. “We have successfully evolved into an active clinical stage company which we have the technology, partnerships and talent, all committed to delivering clinical execution and leadership in the areas of cellular immunotherapy and exosome technology.” Avalon’s stock recently traded up 4.1% to $2.13 a share. Contact the author: [email protected] Follow him on Twitter @PatrickMGraham
0
shares
ShareTweetSavePostSend
 
Credit: Newsflare - Published < > Embed
News video: Car slams into utility pole trailing from truck in China's Changshu

Car slams into utility pole trailing from truck in China's Changshu 00:35

A car slammed into a utility pole trailing behind a truck at a crossing in eastern China's Changshu on June 29. The CCTV video shows a truck turning a corner at an intersection. However, a car driving behind it did not see the pole, driving into and impaling the windscreen. As the pole impaled...

Recent related videos from verified sources

2020 Chevrolet Corvette C8.R Teaser [Video]2020 Chevrolet Corvette C8.R Teaser

Chevrolet begins a new chapter in its storied racing legacy with the introduction of the new mid-engine Corvette race car, known as the C8.R. The C8.R will be Chevrolet's first mid-engine race car to..

Credit: AutoMotions     Duration: 00:39Published

Furious kid kicks car that ran over his mom at a crosswalk [Video]Furious kid kicks car that ran over his mom at a crosswalk

This kid was kickin' mad. When a car knocked down a mother and son as they crossed the street in Chongqing, China, the angry tot shouted at the driver and kicked his car. Police found the man behind..

Credit: nypost     Duration: 00:43Published


Recent related news from verified sources

Genentech Announces New Data on Novel Cd20-cd3 Bispecific Cancer Immunotherapies in People With Difficult-to-Treat Lymphomas

Genentech Announces New Data on Novel Cd20-cd3 Bispecific Cancer Immunotherapies in People With Difficult-to-Treat Lymphomas
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new data on two...
Business Wire

Humanigen Inc wins hematological society award for leukemia treatment presentation

Humanigen Inc (OTCMKTS:HGEN) received an award from the American Society of Hematology (ASH) after presenting an abstract at the organization's annual meeting...
Proactive Investors

You Might Like


Tweets about this

Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2019 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? FeedbackSend us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest
One News® is a registered trademark of One News Page Ltd.